The roundtable included discussions on emerging issues in state advocacy, prior authorization reform, likely impacts of the Big Beautiful Bill and physician wellness.
ACR Calls on Alaska, Montana to Strengthen Rheumatology Care Through Federal Funding
The new Rural Health Transformation Program offers states the chance to apply for CMS funding aimed at transforming rural healthcare.
What to Expect in Chicago at the Practice Innovation Summit
The Practice Innovation Summit, to be held in Chicago Oct. 24–25, offers a roadmap to a smarter, stronger rheumatology practice, led by experts in operations, coding, financial sustainability and more.
Rheuminations: Why Deliberate Practice & Relentless Curiosity Matter
What does it take to become a master in rheumatology? Explore how deliberate practice, relentless curiosity & profound humility are key to true expertise.
How AI Can Make Clinical Rheumatology Research More Efficient & Fruitful
A rheumatologist with a background in biostatistics, data science & bioinformatics discusses the use of artificial intelligence in clinical research.
ACR President Warns: Access to Care Is at Risk Without Medicare Payment Reform
In a recent commentary published by Medscape, ACR President Carol Langford, MD, MHS, issues a stark warning: If Congress does not reform the physician payment system, patients may face increasing difficulty accessing essential medical services.
ACR Responds to Threats to Scientific Integrity at the CDC
On Aug. 29, the ACR issued a strong statement expressing deep concern over recent developments at the agency that could threaten the integrity of science-based public health policy.
Celebrating Interdisciplinary Collaboration: Pathways to Success
Four past ARP presidents mark the organization’s 60th anniversary by examining its evolution alongside significant challenges & opportunities in the field.
Rheum for Everyone, Who Am I? Episode 23 (video)
In this episode, Dr. Kumar talks about the fascinating and intriguing secret lives of rheumatologists—real life superheroes.
Cardiovascular Risks Similar for JAK Inhibitors & bDMARDs
Using data from registries across Europe and Canada, Aymon et al. did not observe an increased incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase (JAK) inhibitors compared with those treated with other biologic disease-modifying anti-rheumatic drugs. Their findings support similar cardiovascular risk profiles for JAK and tumor necrosis factor inhibitors.